OXFORD, UK / ACCESSWIRE / March 25, 2020 / IntraBio Inc., a late-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead compound (IB1001) for the treatment of Niemann-Pick disease Type C (NPC)...Read more
GAINESVILLE, FL – (Businesswire) – March 23, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the Safety Review Committee for its Phase I trial in NPC has determined that Trappsol® Cyclo™ has an acceptable safety profile in patients with Niemann-Pick Disease Type C1...Read more
This webinar has been organised by patient organisations working in the field of Inherited Metabolic Diseases (IMD). It is open to patients and families affected by IMD and it aims to address questions raised by the outbreak of novel coronavirus (COVID-19)...Read more
This is an open call to all patients and families affected by metabolic diseases to submit questions regarding the outbreak of novel coronavirus (COVID-19).
Your questions will be addressed by an expert panel, including Dr Robin Lachmann and Dr Elaine Murphy (Charles Dent Metabolic Unit, National Hospital for Neurology, London).
Information about how to register will follow. Please submit your questions by noon tomorrow (Wednesday 18th March) to: firstname.lastname@example.orgRead more